Literature DB >> 9202476

beta-Tubulin genes and the basis for benzimidazole sensitivity of the opportunistic fungus Cryptococcus neoformans.

Maria Cristina Cruz1, Thomas Edlind1.   

Abstract

The basidiomycete Cryptococcus neoformans causes life-threatening infections in immunocompromised patients, and available chemotherapeutic agents are potentially toxic or have limited efficacy. In vitro, C. neoformans is very sensitive to selected benzimidazole compounds (e.g. albendazole), which act by disrupting microtubules through binding to the beta-tubulin subunit. To understand the basis for this benzimidazole sensitivity, we have characterized C. neoformans beta-tubulin genes and their expression. Analysis of PCR amplification products, genomic and cDNA clones and Southern blots identified two beta-tubulin genes. TUB1 contains seven introns, including one that splits the start codon, and encodes a 447 amino acid protein with > 80% identity to most other beta-tubulins. A partial sequence of TUB2 revealed a higher density of introns and a considerably more divergent beta-tubulin. The relative expression of TUB1 to TUB2 determined by reverse-transcription PCR was about 3:1, consistent with a more limited role for the TUB2 product. Comparisons of beta-tubulin sequences from C. neoformans and from various benzimidazole-sensitive and -resistant organisms strongly suggest that the TUB1 product represents the primary benzimidazole target. This was supported by the identification of a His6 to Gln change in TUB1 from three independently isolated albendazole-resistant mutants.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9202476     DOI: 10.1099/00221287-143-6-2003

Source DB:  PubMed          Journal:  Microbiology (Reading)        ISSN: 1350-0872            Impact factor:   2.777


  12 in total

1.  Liver fluke β-tubulin isotype 2 binds albendazole and is thus a probable target of this drug.

Authors:  Emma Chambers; Louise A Ryan; Elizabeth M Hoey; Alan Trudgett; Neil V McFerran; Ian Fairweather; David J Timson
Journal:  Parasitol Res       Date:  2010-07-31       Impact factor: 2.289

2.  Effect of auristatin PHE on microtubule integrity and nuclear localization in Cryptococcus neoformans.

Authors:  Tanja Woyke; Robert W Roberson; George R Pettit; Günther Winkelmann; Robin K Pettit
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

3.  Molecular characterization of the plasma membrane H(+)-ATPase, an antifungal target in Cryptococcus neoformans.

Authors:  P Soteropoulos; T Vaz; R Santangelo; P Paderu; D Y Huang; M J Tamás; D S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

4.  In vitro activities and postantifungal effects of the potent dolastatin 10 derivative auristatin PHE.

Authors:  T Woyke; G R Pettit; G Winkelmann; R K Pettit
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

5.  Isolation and sequence analysis of a beta-tubulin gene from arbuscular mycorrhizal fungi.

Authors:  Zola Msiska; Joseph B Morton
Journal:  Mycorrhiza       Date:  2009-05-15       Impact factor: 3.387

6.  Encephalitozoon cuniculi Genotype III Evinces a Resistance to Albendazole Treatment in both Immunodeficient and Immunocompetent Mice.

Authors:  Bohumil Sak; Klára Brdíčková; Nikola Holubová; Dana Květoňová; Lenka Hlásková; Martin Kváč
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

7.  Differential gene expression in auristatin PHE-treated Cryptococcus neoformans.

Authors:  Tanja Woyke; Michael E Berens; Dominique B Hoelzinger; George R Pettit; Günther Winkelmann; Robin K Pettit
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

8.  Fenbendazole Controls In Vitro Growth, Virulence Potential, and Animal Infection in the Cryptococcus Model.

Authors:  Haroldo C de Oliveira; Luna S Joffe; Karina S Simon; Rafael F Castelli; Flavia C G Reis; Arielle M Bryan; Beatriz S Borges; Lia C Soares Medeiros; Anamelia L Bocca; Maurizio Del Poeta; Marcio L Rodrigues
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

9.  Treatment with anthelminthics during pregnancy: what gains and what risks for the mother and child?

Authors:  Alison M Elliott; Juliet Ndibazza; Harriet Mpairwe; Lawrence Muhangi; Emily L Webb; Dennison Kizito; Patrice Mawa; Robert Tweyongyere; Moses Muwanga
Journal:  Parasitology       Date:  2011-08-03       Impact factor: 3.234

10.  Predicting Resistance by Mutagenesis: Lessons from 45 Years of MBC Resistance.

Authors:  Nichola J Hawkins; Bart A Fraaije
Journal:  Front Microbiol       Date:  2016-11-15       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.